Clinical Trial Update: Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction [Phase 4]

View source ↗

Summary

This clinical trial update describes a prospective, single-arm study evaluating irinotecan liposome injection with platinum-based chemotherapy, immune checkpoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Immune checkpoint inhibitors (unspecified)
• Irinotecan hydrochloride liposome injection (irinotecan liposome injection)
• Platinum-based chemotherapy (unspecified)

Snippet

Sponsor: China Medical University, China | Conditions: Small Cell Lung Cancer | Phase 4 | Status: NOT_YET_RECRUITING